These studies allowed FDA in 2019 and EMA in 2020 to approve Pembrolizumab in recurrent and/or metastatic HNSCC in combination with platinum and fluorouracil regardless of PD-L1 status and in monotherapy in patients with CPS≥1 (Figure 4). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.